# reload+after+2024-01-21 13:47:40.377260
address1§101 Hartwell Avenue
city§Lexington
state§MA
zip§02421
country§United States
phone§781 761 4646
fax§781 240 0464
website§https://www.t2biosystems.com
industry§Diagnostics & Research
sector§Healthcare
longBusinessSummary§T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
fullTimeEmployees§158
companyOfficers§[{'maxAge': 1, 'name': 'Mr. John J. Sperzel III, B.Sc.', 'age': 60, 'title': 'President, CEO & Chairman', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 865500, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John M. Sprague CPA', 'age': 65, 'title': 'Chief Financial Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 482333, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael Terrence Gibbs Esq.', 'age': 52, 'title': 'Senior VP, General Counsel & Company Secretary', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 487333, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kelley J. Morgan', 'age': 47, 'title': 'Chief People Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brett A. Giffin', 'age': 64, 'title': 'Chief Commercial Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Roger  Smith Ph.D.', 'age': 58, 'title': 'Senior Vice President of Science Research & Development', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.208
priceToSalesTrailing12Months§2.13619
currency§USD
dateShortInterest§1702598400
forwardEps§-8.44
exchange§NCM
quoteType§EQUITY
shortName§T2 Biosystems, Inc.
longName§T2 Biosystems, Inc.
firstTradeDateEpochUtc§1407418200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f1bc2494-0bab-33c5-b4f8-3d62d4000348
gmtOffSetMilliseconds§-18000000
targetHighPrice§12.0
targetLowPrice§5.35
targetMeanPrice§8.68
targetMedianPrice§8.68
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§2
quickRatio§0.459
grossMargins§-2.8322299
ebitdaMargins§0.0
trailingPegRatio§None
